Financials in USD. Standardized financial statements.
A compact view of how Doseology Sciences Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue? | $31,257 | $98,522 | $43,088 | $16,048 | $0 |
| Revenue Growth? | -68.3% | +128.7% | +168.5% | 0.0% | 0.0% |
| Cost of Revenue? | $23,671 | $26,435 | $1,802 | $164,427 | $0 |
| Gross Profit? | $18,885 | $72,087 | $41,286 | -$148,379 | $0 |
| Gross Margin? | +60.4% | +73.2% | +95.8% | -924.6% | 0.0% |
| Operating Expenses? | $490,491 | $449,720 | $873,459 | $1.67M | $1.57M |
| Operating Income? | -$346,394 | -$377,633 | -$767,133 | -$1.81M | -$1.56M |
| EBITDA? | -$328,900 | -$319,478 | -$1.80M | -$1.65M | -$1.40M |
| Income Before Tax | -$328,900 | -$339,848 | -$1.78M | -$1.94M | -$1.63M |
| Income Tax Expense | $0 | $0 | $36,136 | $0 | $0 |
| Net Income? | -$328,900 | -$339,848 | -$1.78M | -$1.94M | -$1.63M |
| EPS? | $-0.07 | $-0.08 | $-0.04 | $-0.05 | $-0.04 |
| Diluted EPS? | $-0.07 | $-0.08 | $-0.04 | $-0.05 | $-0.04 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality